255
Participants
Start Date
February 28, 2022
Primary Completion Date
February 9, 2023
Study Completion Date
February 9, 2023
JS002
JS002:150mg(1mL) Q2W PFS, Placebo: 1mL Q2W PFS.
Placebo
JS002:150mg(1mL) Q2W AI, Placebo: 1mL Q2W AI.
Beijing Anzhen Hospital,Capital Medical University, Beijing
Peking University Third Hospital, Beijing
China-Japan Friendship Hospital, Beijing
Dalian Municipal Central Hospital, Dalian
The First Affiliated Hospital of Jinzhou Medical University, Jinzhou
The First Hospital of Jilin University, Changchun
The Fourth Affiliated Hospital of Harbin Medical University, Harbin
Daqing People's Hospital, Daqing
Changzhou Second People's Hospital, Changzhou
Affiliated Hospital of Xuzhou Medical University, Xuzhou
Tianjin People's Hospital, Tianjin
Taizhou Hospital Of Zhejiang Province, Taizhou
The First Affiliated Hospital of Wenzhou Medical University, Wenzhou
Nanchang First Hospital, Nanchang
Nanchang Third Hospital, Nanchang
The Second Affiliated Hospital of Nanchang University, Nanchang
The First Affiliated Hospital of Fujian Medical University, Fuzhou
The Second Xiangya Hospital Of Central South University, Changsha
Jingzhou Central Hospital, Jingzhou
First Affiliated Hospital of Zhengzhou University, Zhengzhou
Xianyang Hospital of Yan'an University, Xianyang
Shanghai Junshi Bioscience Co., Ltd.
OTHER